Skip to content
DataLookout
Menu

GRACENCT05636709

National GMA Post-market Clinical Follow-up Study (GRACE)

StatusActive, Not Recruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved 12 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Jun 30, 2026 to Jun 30, 2027 Show 4 more changesShow less
    • Eligibility criteria expanded, about 6 words
    • Enrollment closed, study ongoing
    • Secondary endpoints: details revised at 9 of 11 entries
    • Site details revised at 30 of 30 sites
  2. Notable Primary and study completion dates pushed to Jun 30, 2026
    • Site details revised at 20 of 30 sites
    v4
  3. Minor Study sites: 29 to 30v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of patients achieving steroid-free clinical remission at 6 months after completion of GMA therapy
Timeframe: 6 months

Secondary (11)

Define the regimens used for GMA in actual clinical practice.
Early clinical remission rate
6- and 12-month remission rates completion of GMA therapy
Sustained clinical remission rate
6- and 12-month clinical response rates
Show 6 moreShow less
Rate of patients receiving GMA as maintenance and its efficacy
Rate of patients requiring steroids and mean dose during follow-up
Changes in faecal calprotectin and C-reactive protein (CRP) biomarkers during treatment
Rate of treatment-related adverse events (AEs) and seriousness
Change in patients' quality of life
Number of patients requiring surgery

Arms and interventions

Devices: Adacolumn

Sites

30 sites in 1 country